DAA trio offers high efficacy in relapsed HCV-1

  • J Hepatol
  • 4 Jun 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • A 12-week course of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX; Vosevi) is highly effective for clearing HCV-1 in patients who relapse after initial treatment with combination direct-acting antivirals (DAAs).

Why this matters

  • SOF/VEL/VOX has not previously been studied in patients with HIV and/or HBV, or in patients with prior poor adherence/noncompletion of DAA therapy.

Study design

  • Phase 2b RESOLVE study of 77 patients with relapsed HCV-1 (genotype 1a, 75%) receiving 12 weeks of SOF/VEL/VOX.
  • All had previously received DAA combination therapy, primarily ledipasvir/sofosbuvir (Harvoni, 89%).
  • Primary endpoint: sustained virologic response at 12 weeks posttreatment (SVR12).
  • Funding: Gilead Sciences.

Key results

  • 22.1% of patients were HIV-positive and on antiretroviral therapy (dolutegravir-based, 47%), 2.6% were HBV-positive, and 28.6% had failed to complete a prior DAA regimen.
  • 50.6% reported prior intravenous drug use and 32.5% reported heavy alcohol use.
  • 40.2% of patients had compensated cirrhosis, and 36.4% had stage ≤II hepatic fibrosis.
  • Intent-to-treat SVR12 rate was 90.9% (95% CI, 82.1%-95.8%).
    • SVR12 rate in HIV-coinfected patients was 82.4%.
    • SVR12 rate in patients who had failed to complete prior therapy was 81.8%.
  • Per-protocol analysis yielded an SVR12 rate of 98.6% (70/71).
  • Adverse events were generally mild and most commonly included fatigue (27.3%), headache (24.7%), and diarrhea (20.8%).

Limitations

  • Open-label design.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit